Piramal Pharma (NSE:PPLPHARMA) Current Deferred Revenue: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
51 GF Score
Price ₹214.40
GF Value ₹191.25
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Piramal Pharma Current Deferred Revenue?

Piramal Pharma NSE:PPLPHARMA -1.96% 51 Current Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 51/100 and a GF Value™ of ₹191.25 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Piramal Pharma's current deferred revenue for the quarter that ended in Jun. 2026 was ₹0 Mil.

Piramal Pharma Current Deferred Revenue Related Terms

Piramal Pharma Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Piramal Pharma's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma Current Deferred Revenue Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Piramal Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:PPLPHARMA
51GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₹0 Mil mean?
Piramal Pharma (NSE:PPLPHARMA) has a Current Deferred Revenue of ₹0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Piramal Pharma and its competitors.
Is Piramal Pharma's Current Deferred Revenue too high?
Piramal Pharma's current Current Deferred Revenue is ₹0 Mil. Overall, Piramal Pharma has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Current Deferred Revenue compare to ZTS?
Piramal Pharma's Current Deferred Revenue of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Piramal Pharma and its competitors. Piramal Pharma's current Current Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹191.25, compared to a current price of ₹214.40 — trading 12.1% above its estimated fair value. The current Current Deferred Revenue is ₹0 Mil. Piramal Pharma's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Current Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued. The current stock price of ₹214.40 is trading 12.1% above its estimated GF Value™ of ₹191.25. GuruFocus considers Piramal Pharma to be Modestly Overvalued.

Key valuation signals for NSE:PPLPHARMA:

  • Current Deferred Revenue: ₹0 Mil
  • GF Value™: ₹191.25 vs. price of ₹214.40 (12.1% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
51GF Score

Get the complete analysis for NSE:PPLPHARMA

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹214.40
Price
₹191.25
GF Value